Epivax
EpiVax is a 21-year old privately held biotechnology company located in Providence, Rhode Island. Scientists at EpiVax, led by co-founders Annie De Groot, MD and Bill Martin, lead in the fields of immunogenicity risk assessment and computational vaccinology with expertise in T cell epitope prediction, immune modulation, and rapid vaccine design. EpiVax's broad portfolio of projects includes vaccines and immunotherapies for infectious diseases, autoimmunity and cancer. EpiVax's proprietary in silico immunogenicity screening toolkits for therapeutics and vaccines, ISPRI and iVAX, are employed in advancing the research of a global roster of companies.
About Epivax
Founded
1998Estimated Revenue
$1M-$10MEmployees
11-50Funding / Mkt. Cap
$7MCategory
Sector
Health CareIndustry Group
Pharmaceuticals, Biotechnology & Life SciencesIndustry
BiotechnologyLocation
City
ProvidenceState
Rhode IslandCountry
United StatesEpivax
Find your buyer within Epivax